Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pBC.1 plasmid DNA vaccine
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
pBC.1 is a multi-antigen plasmid DNA (pDNA) vaccine designed for the prevention and treatment of breast cancer. Developed through a collaboration involving the National Cancer Institute (NCI), Mayo Clinic, and MRIGlobal, the vaccine utilizes the pUMVC4a vector and 2A peptide technology to enable the coordinated expression of multiple tumor-associated antigens (TAAs). Specifically, pBC.1 encodes the extracellular and intracellular domains of Human Epidermal Growth Factor Receptor 2 (HER2) and Mucin 1 (MUC1). As a gene therapy modality, it offers transient, non-integrating expression of these antigens to stimulate an immune response against breast cancer cells. The vaccine is formulated in saline sodium citrate (SSC) to maintain structural integrity, specifically supercoiled topology, which serves as a critical quality attribute for functional potency.
- Other names
- pBC.1 plasmidpBC.1 DNA vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on pBC.1 plasmid DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pBC.1 plasmid DNA vaccine.